To address the inequitable global access to monoclonal antibodies (mAbs), particularly in low- and middle-income countries (LMICs).
Approach:
Key Findings:
Over 130 mAbs are approved in the US, but only 16 are on the WHO Essential Medicines List.
Nirsevimab for RSV prevention could improve access to mAbs in LMICs.
Combining mAbs could create a viable production scale to reduce costs.
Interpretation:
The integration of long-acting infectious disease mAbs with existing WHO Essential Medicines List mAbs could create a comprehensive approach to improving global access to these therapies.
Limitations:
The approach relies on political mobilization and structural changes.
Current manufacturing and distribution capacities may not meet increased demand.
Conclusion:
Connecting long-acting infectious disease mAbs with existing mAbs could enhance access in global health.
